This gene test determines a patient’s risk for progression to advanced Age-related Macular Degeneration (AMD) within 2, 5 or 10 years. The test also provides a pharmacogenetic recommendation related to

AREDS supplements for AMD.


Learn more

Corporate Headquarters: ArcticDx Inc.

MaRs Centre, 661 University Ave.  Suite 455

Toronto, Ontario  M5G 1M1  Canada


T: 1 (866) 964-5182                        F: 1 (866) 964-5184


Email: or

© Arctic Group Of Companies. All Rights Reserved.

Privacy Policy. Terms and Conditions